CTLA4 : B7-2[Biotinylated] Inhibitor Screening Assay Kit

Catalog #

79658

$1,205 *

Size: 96 reactions

Qty

Bulk/Custom

Add to Favorites

*US Pricing only. For international pricing, please contact your local distributor.

●

Purchase

●

Description

The CTLA4:B7-2[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of CTLA4:B7-2-biotin interaction. The key to this kit is the high sensitivity of detection of CTLA4 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, CTLA4 is coated on a 96-well plate. Next, B7-2-biotin is incubated with CTLA4 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

This product has been cited 1 time.

●

Synonyms

Cytotoxic T-lymphocyte-associated protein 4 CD152, T-lymphocyte activation antigen CD86, B7.2, FUN-1, B70, BU63, CD86, B72, CTLA-4

●

Product Data Gallery

Product Info

Storage and Usage

Citations1

Assay Kit Format

Chemiluminescent

Supplied As

This kit comes in a convenient 96-well format, with CTLA4 (CD152), purified biotin-labeled B7-2 (CD86), streptavidin-labeled HRP, and assay buffer for 100 binding reactions.

Format

Catalog #	Component	Amount	Storage
71149	CTLA4 (CD152), Fc-tag	10 µg	-80°C	(Avoid freeze/ thaw cycles!)
71159	B7-2 (CD86), Fc-Biotin-labeled	3 µg	-80°C
79742	Streptavidin-HRP	10 µl	+4°C
79311	3x Immuno Buffer 1	50 ml	-20°C
79728	Blocking Buffer 2	50 ml	+4°C
	HRP chemiluminescent substrate A (transparent bottle)	6 ml	+4°C
	HRP chemiluminescent substrate B (brown bottle)	6 ml	+4°C
79699	White 96-well microplate	1	+4°C

UniProt #

CTLA4: P16410; B7-2: P42081

Background

B7-2 (CD86) signaling through CTLA4 (CD152) has been shown to inhibit T- cell activation. This co-inhibitory pathway can be overactive in many tumors, enabling cancers to escape the host’s immune system. CTLA4-blocking antibodies, including Ipilimumab (Yervoy) and Tremelimumab, have shown clinical efficacy in treating cancer.

References

1. Ohtani, H., et al., Lab Invest. 1997; 77(3): 231-241.
2. Robert, C., et al., N. Engl. J. Med. 2011; 364: 2517-2526.

Storage/Stability

6 months from date of receipt when stored as directed.

Instructions for Use

See assay kit data sheet for detailed protocol

Shipping Temperature

-80°C (dry ice)

Warnings

Avoid freeze/thaw cycles.

Disclaimers and Limitations

BPS Bioscience assay kits are validated using the listed components according to our specific protocol. Any deviations to kit components or protocols, such as using different proteins, cell/tissue lysates, or buffers (including using the same component from other commercial sources) will void any warranties on the performance of the assay kit and is not recommended.

End-users should immediately report any issues to [email protected] upon receipt of the kit, such as missing components, damaged vials, no dry ice, etc.

Scientific Category

Immunotherapy/Cell Surface Receptor

Regulatory Status

Research Use Only

Skip to the end of the images gallery

Skip to the beginning of the images gallery

CTLA4 : B7-2[Biotinylated] Inhibitor Screening Assay Kit

PRODUCTS

SERVICES

RESOURCES

COMPANY